# Halozyme Therapeutics (HALO): value investors who own it

2 value investors held Halozyme Therapeutics in their Q2 2026 13F, led by Torray Investment Partners, Pzena Investment Management.

## 13F holders

| Manager | Portfolio | Value | Change | Quarters held |
| --- | --- | --- | --- | --- |
| Torray Investment Partners | 0.4% | $3.0m | Added +1.4% | 39 |
| Pzena Investment Management | 0.0% | $317k | Unchanged | 4 |

## Directors buying and selling (Form 4, last 12 months)

| Date | Who | Role | Bought or sold | Shares | Value |
| --- | --- | --- | --- | --- | --- |
| 2026-10-08 | Torley Helen | PRESIDENT AND CEO | Sold | 11900 | $1.3m |
| 2026-10-08 | Torley Helen | PRESIDENT AND CEO | Sold | 4810 | $520k |
| 2026-10-08 | Torley Helen | PRESIDENT AND CEO | Sold | 3090 | $337k |
| 2026-10-08 | Torley Helen | PRESIDENT AND CEO | Sold | 200 | $22k |
| 2026-10-07 | Torley Helen | PRESIDENT AND CEO | Sold | 10300 | $1.2m |
| 2026-10-07 | Torley Helen | PRESIDENT AND CEO | Sold | 8600 | $955k |
| 2026-10-07 | Torley Helen | PRESIDENT AND CEO | Sold | 900 | $102k |
| 2026-10-07 | Torley Helen | PRESIDENT AND CEO | Sold | 200 | $23k |
| 2026-10-06 | Torley Helen | PRESIDENT AND CEO | Sold | 9920 | $1.1m |
| 2026-10-06 | Torley Helen | PRESIDENT AND CEO | Sold | 6000 | $656k |
| 2026-10-06 | Torley Helen | PRESIDENT AND CEO | Sold | 2300 | $248k |
| 2026-10-06 | Torley Helen | PRESIDENT AND CEO | Sold | 1780 | $197k |
| 2026-10-01 | Posard Matthew L. | Director | Sold | 3300 | $358k |
| 2026-10-01 | Posard Matthew L. | Director | Sold | 1100 | $121k |
| 2026-10-01 | Posard Matthew L. | Director | Sold | 730 | $78k |
| 2026-10-01 | Posard Matthew L. | Director | Sold | 100 | $11k |
| 2026-09-16 | Posard Matthew L. | Director | Sold | 8896 | $961k |
| 2026-09-16 | Posard Matthew L. | Director | Sold | 4000 | $436k |
| 2026-09-16 | Posard Matthew L. | Director | Sold | 3100 | $329k |
| 2026-09-16 | Posard Matthew L. | Director | Sold | 3000 | $320k |

Source: SEC filings, via moatshark (https://www.moatshark.com/s/halo). Values traded and returns are estimates. Not investment advice. Built 2026-10-23.